AI Article Synopsis

  • Bezafibrate could be beneficial for heart transplant patients with high Lp(a) levels.
  • The study indicates a potential treatment option for managing this specific lipid marker.
  • Higher Lp(a) levels are associated with increased cardiovascular risk, making this finding important for patient care.

Article Abstract

Our results suggest that bezafibrate may be useful in the treatment of high Lp(a) levels in heart transplant patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0002-9149(99)80642-0DOI Listing

Publication Analysis

Top Keywords

comparison lovastatin
4
lovastatin bezafibrate
4
bezafibrate lipoproteina
4
lipoproteina plasma
4
plasma levels
4
levels cardiac
4
cardiac transplant
4
transplant recipients
4
recipients bezafibrate
4
bezafibrate treatment
4

Similar Publications

The increasing use of red yeast rice (RYR) as a natural supplement to manage blood cholesterol levels is driven by its active compound, monacolin K (MK), which is chemically identical to the statin drug lovastatin (LOV). Despite its growing popularity, concerns persists regarding the safety and efficacy of RYR compared to pure statins. This study aimed to evaluate the phytochemical composition, pharmacological effects, and safety profile of various RYR samples in comparison with LOV.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on creating and testing self-nanoemulsifying drug delivery systems (SNEDDS) with simvastatin to boost its oral bioavailability.
  • Two specific formulations, EO 5 and CL 14, were shown to emulsify quickly, have very small droplet sizes, and achieve near-complete drug release within 2 hours.
  • In vivo tests revealed that formulation EO 5 significantly improved simvastatin bioavailability, leading to much greater effectiveness compared to traditional simvastatin suspension.
View Article and Find Full Text PDF

Elevated cerebrospinal fluid glial fibrillary acidic protein levels in Smith-Lemli-Opitz syndrome.

Mol Genet Metab

October 2024

Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. Electronic address:

Smith-Lemli-Opitz syndrome (SLOS) is a rare, multiple malformation/intellectual disability disorder caused by pathogenic variants of DHCR7. DHCR7 catalyzes the reduction of 7-dehydrocholesterol (7DHC) to cholesterol in the final step of cholesterol biosynthesis. This results in accumulation of 7DHC and a cholesterol deficiency.

View Article and Find Full Text PDF

Background: Variable benefits have been reported from the adjunctive use of simvastatin and the 5HT3 receptor antagonist, ondansetron, in patients with schizophrenia. We investigated their independent efficacy and possible synergy to improve negative symptoms of schizophrenia within a single trial.

Methods: A 6-month, randomised, double-blind, placebo-controlled trial with a 4-arm, 2 × 2 factorial design, in three centres in Pakistan.

View Article and Find Full Text PDF

The use of topical antimicrobials in wound healing presents challenges like risk of drug resistance and toxicity to local tissue. Simvastatin (SIM), a lipid-lowering agent which reduces the risk of cardiovascular events, is repurposed for its pleiotropic effect in wound healing. A bioactive bioadhesive polymer-based film forming spray (FFS) formulation of SIM was designed using chitosan, collagen, hyaluronic acid and optimised by employing the DoE approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!